Meta Pixel

News and Announcements

Positive results for Walker Capital May returns

  • Published June 06, 2019 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Highlights

  • May saw 75% positive returns across all Walker Capital strategies.
  • Swing Trading, Multi-Strategy and the High Growth Strategy all posted positive returns at 3.39%, 1.1% and 3.85% respectively.
  • The Growth Strategy posted its second consecutive loss of -0.12% for May.

May saw 75% positive returns across all Walker Capital strategies.

Swing Trading, based on fundamental and technical analysis using trends and Fibonacci levels posted its fourth consecutive positive return of 3.39% net return for May.

The Multi-Strategy, an algorithmic trading system on Forex and commodities which identifies price patterns for emerging and breakout opportunities improved on its April return sitting at a 1.19% net return for May.

Designed to perform in market volatility and difficult market conditions, the High Growth Strategy had a promising swing back to a positive return 3.85% net return for May.

The Growth Strategy, based on fundamental and technical analysis using trends and Fibonacci levels posted its second consecutive loss of -0.12% for May.

 

About Walker Capital

Walker Capital is to raise up to $900,000 for 20% in equity. The capital will be used to fund the expansion of the Company as it increases its marketing campaign aimed at expanding its client base and developing an investment platform for its clients.

Register Interest

Capital Insights
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship

From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now